Aurobindo Pharma shares saw a huge jump in the early trading session after the company received the US Food and Drug Administration nod for the manufacturing and marketing of Mometasone Furoate Monohydrate nasal spray, 50 mcg/spray.
At around 10:53 am, the shares were trading up 1.55% at ₹1,005.75.
The nasal spray with the strength bioequivalent and therapeutically equivalent to the The RLD, Nasonex Nasal Spray, from Organon LLC, is expected to be launched in the first quarter of the financial year 2025.
Mometasone Furoate Monohydrate nasal spray is used primarily for the treatment of nasal symptoms of seasonal allergic and perennial allergic rhinitis.
In a regulatory filing, Aurobindo Pharma expressed its excitement about the USFDA’s approval, account the determined market size of Mometasone Furoate Monohydrate nasal spray. According to IQVIA MAT January 2024 data, the determined market size for Mometasone Furoate Monohydrate nasal spray is US$44.5 million for the twelve months ending in January 2024 .
Aurobindo Pharma, with this latest approval, now has a total of 507 ANDA approvals from the USFDA which includes 488 final approvals and 19 tentative approvals.
The company continues to grow in terms of its product portfolio. This contributes to Aurobindo Pharma’s commitment to providing access to affordable medicines in its fight to meet the healthcare needs of patients globally.
